Teijin Limited and BioVaram, the brand name of the UR Advanced Therapeutics Pvt Ltd. (URAT), announced today that they have signed a business alliance agreement to explore opportunities for expanding usage of Teijin Group’s implantable medical devices and regenerative medicine products in India, as well as introducing BioVaram’s product portfolio into the Japanese market..

帝人株式会社与UR Advanced Therapeutics Pvt Ltd.（URAT）的品牌BioVaram今日宣布，双方已签署业务联盟协议，旨在探索扩大帝人集团的可植入医疗设备和再生医学产品在印度的使用机会，同时将BioVaram的产品组合引入日本市场。

The two companies share a vision to address unmet medical needs in Japan—one of the world’s most advanced healthcare markets—and India, where healthcare innovation is accelerating. This alliance aims to leverage each company’s strengths to deliver cutting-edge solutions across both nations.

这两家公司有着共同的愿景，即满足日本（全球最先进的医疗市场之一）和印度（其医疗创新正在加速）尚未满足的医疗需求。该联盟旨在利用每家公司的优势，在两国提供尖端的解决方案。

Under the agreement, Teijin and BioVaram will explore:

根据协议，帝人和BioVaram将探索：

Regulatory approval and commercialization of SYNFOLIUMⓇ, a cardiovascular repair patch by Teijin Medical Technologies Co., Ltd., in India.

印度帝人医疗技术有限公司的心血管修复补片SYNFOLIUMⓇ的监管批准和商业化。

Opportunities for expanding use of Japan Tissue Engineering Co., Ltd.’s regenerative medicine products in India. Japan Tissue Engineering (J-TEC) is part of the Teijin Group.

在日本组织工程公司（Japan Tissue Engineering Co., Ltd.）的再生医学产品在印度扩展使用的机遇。日本组织工程公司（J-TEC）是帝人集团（Teijin Group）的一部分。

Development and commercialization in Japan of BioVaram technologies, including exosome-based diagnostics and therapeutics, Extracellular Matrix mimics, and bio-derived materials such as Type I atelocollagen.

在日本开发和商业化BioVaram技术，包括基于外泌体的诊断和治疗、细胞外基质模拟物以及生物衍生材料，如I型去端肽胶原蛋白。

Takayuki Nakano, Ph.D., Mission Executive and General Manager, Regenerative Medicine & Implantable Medical Device Division of Teijin Limited., said “The partnership with UR Advanced Therapeutics marks a highly significant step toward Teijin’s global expansion in the fields of regenerative medicine and implantable medical devices.

中野隆之博士，帝人有限公司再生医学与植入式医疗器械部门的执行董事兼总经理表示：“与UR Advanced Therapeutics的合作标志着帝人在再生医学和植入式医疗器械领域全球扩展的重要一步。”

By combining the exceptional technological capabilities and extensive expertise of both companies across the distinct markets of Japan and India, we are confident in our ability to deliver innovative therapies that address unmet medical needs in both countries.”.

通过结合两家公司在日本和印度不同市场的卓越技术能力和广泛专业知识，我们有信心提供满足两国未满足医疗需求的创新疗法。"

Jaganmohan Reddy, Founder and CEO of UR Advanced Therapeutics, remarked, “This MoU with Teijin Limited marks the beginning of a journey to bring India’s next-generation biotech innovations onto the global stage. It reinforces BioVaram’s vision to build transformative biotech innovations in India together with global partners.

UR Advanced Therapeutics创始人兼首席执行官Jaganmohan Reddy表示：“与帝人有限公司的这份谅解备忘录标志着将印度下一代生物技术创新推向全球舞台的旅程的开始。这也进一步巩固了BioVaram与全球合作伙伴共同在印度打造变革性生物技术创新的愿景。”

This partnership strengthens our capabilities in research, innovation, and scalable manufacturing of advanced tissue engineering products, while enabling Teijin to take BioVaram’s products to global markets. Together, we are shaping a future where biotechnology is transformative, sustainable, and deeply humane” .”.

这一合作加强了我们在先进组织工程产品研究、创新和规模化制造方面的能力，同时使帝人能够将BioVaram的产品推向全球市场。我们共同塑造一个生物技术具有变革性、可持续性和深刻人文关怀的未来。

Teijin established its Regenerative Medicine and Implantable Medical Devices division in 2022 by, integrating Teijin Medical Technologies, which manufactures bioabsorbable implantable devices; J-TEC, a pioneer in regenerative medicine; and Teijin Regenet Co., Ltd., a dedicated contract development and manufacturing organization (CDMO) for regenerative therapies.

帝人于2022年通过整合生产生物可吸收植入装置的帝人医疗技术公司、再生医学领域的先驱J-TEC公司以及专注于再生疗法的合同开发与制造组织（CDMO）帝人Regenet有限公司，成立了其再生医学和可植入医疗设备部门。

The group continues to grow with a mission to provide treatments that restore lost tissue and functions for patients..

该集团继续发展壮大，其使命是为患者提供恢复丧失的组织和功能的治疗方法。

Headquartered in Hyderabad, India, BioVaram is a rapidly growing biotechnology company recognized for its innovative regenerative medicine solutions. BioVaram offers AI-designed peptides, exosomes for therapeutic and diagnostic use, and bio-derived materials. The company has earned multiple awards, including being named a “Top 5 Startup” at BioAsia 2024..

总部位于印度海得拉巴的BioVaram是一家快速发展的生物技术公司，以其创新的再生医学解决方案而闻名。BioVaram提供人工智能设计的肽、用于治疗和诊断的外泌体以及生物衍生材料。该公司屡获殊荣，包括在2024年BioAsia上被评为“五大初创企业”之一。

Moving forward, the two companies will assess business feasibility, regulatory pathways, technical integration, and market needs to advance these initiatives. They will also collaborate on product development and manufacturing in cell and gene therapy, and pursue plans for introducing SYNFOLIUMⓇ in India.

展望未来，两家公司将评估业务可行性、监管路径、技术整合和市场需求，以推进这些计划。他们还将在细胞和基因治疗领域合作进行产品开发和制造，并寻求在印度推出SYNFOLIUMⓇ的计划。

By sharing market insights and regulatory information, Teijin and BioVaram aim to build a robust partnership that accelerates innovation in both countries..

通过分享市场洞察和监管信息，帝人和BioVaram旨在建立一个强有力的合作伙伴关系，推动两国的创新加速。

About the Teijin Group

关于帝人集团

Teijin (TSE: 3401) is a technology-driven global group with two core businesses: high-performance materials and healthcare solutions. Established in 1918 as Japan’s first rayon manufacturer, Teijin today comprises some 170 companies employing 20,000 people. Teijin is committed to its Purpose, “Pioneering solutions together for a healthy planet.” Teijin works together with employees and external partners to achieve its Long-Term Vision, “To be a company that supports the society of the future.” Teijin posted consolidated revenue of JPY 1,005.5 billion and total assets of JPY 1,061.3 billion in the fiscal year ending March 31, 2025..

帝人（TSE：3401）是一家以技术为导向的全球集团，拥有两大核心业务：高性能材料和医疗保健解决方案。公司成立于1918年，是日本首家人造丝制造商，如今已发展为包含约170家公司的企业，员工总数达20,000人。帝人致力于实现其企业宗旨：“共同开创解决方案，促进地球健康。”帝人与员工及外部合作伙伴携手，努力实现其长期愿景：“成为支持未来社会的企业。”截至2025年3月31日的财年，帝人合并收入为1,005.5亿日元，总资产为1,061.3亿日元。

Teijin Group remains committed to achieving its fiscal 2030 sales target of JPY 20 billion in regenerative medicine by actively capturing global demand, strengthening its business foundation through facility expansion and talent development, and pursuing strategic partnerships worldwide.

帝人集团将继续致力于实现其在再生医学领域2030财年达到200亿日元的销售目标，积极把握全球需求，通过设施扩张和人才培养加强业务基础，并在全球范围内寻求战略合作伙伴关系。

Press Contacts

媒体联系人

Corporate Communication Department, Teijin Limited

帝人有限公司企业传播部

[email protected]

电子邮件地址

About BioVaram

关于BioVaram

BioVaram, the brand name of the UR Advanced Therapeutics (est. 2020), is a tissue engineering and regenerative medicine company pioneering AI-enabled peptide design for biomimetic materials, stem cells, and exosomes. Initially bootstrapped, the company later secured support from the ASPIRE Seed Fund and the BIRAC BIG Grant, followed by investments from Bhavya Constructions, Dr.

BioVaram，UR Advanced Therapeutics（成立于2020年）的品牌名称，是一家组织工程与再生医学公司，率先利用人工智能进行仿生材料、干细胞和外泌体的肽设计。公司最初自筹资金，后来获得了ASPIRE种子基金和BIRAC BIG资助的支持，随后还得到了Bhavya Constructions和Dr.的投资。

K. I. Varaprasad Reddy, Founder of Shantha Biotechnics and Mr. Manoj Namburu and Consortium..

K. I. Varaprasad Reddy，Shantha Biotechnics创始人，Manoj Namburu先生及财团。

With these strategic investments, BioVaram is rapidly growing and building a state-of-the-art facility for regenerative medicine, focused on advancing AI-driven biomaterials, exosome technologies, and next-generation therapeutic platforms. The company recently launched its first AI-designed peptide product for cell death detection and exosome identification and purification—marking a breakthrough in translating computational innovation into practical healthcare solutions..

通过这些战略投资，BioVaram正在迅速发展，并建造一个专注于推进人工智能驱动的生物材料、外泌体技术以及下一代治疗平台的再生医学尖端设施。该公司最近推出了其首款用于细胞死亡检测和外泌体识别与纯化的AI设计肽产品，这标志着将计算创新转化为实际医疗解决方案的一项重大突破。

Guided by the mentorship of Dr. K. I. Varaprasad Reddy, the architect of India’s first recombinant vaccine, BioVaram is committed to transforming innovation into accessible therapies that strengthen India’s legacy of equitable and affordable healthcare.

在印度第一支重组疫苗的缔造者K. I. Varaprasad Reddy博士的指导下，BioVaram致力于将创新转化为可及的疗法，巩固印度公平且负担得起的医疗保健传统。

The company’s pioneering work has been recognized with multiple honours, including winning the Maharathi Challenge 2025, being selected for Booth Visit by the Prime Minister of India, and recognition among the Top 5 Startups at BioAsia 2024. These achievements underscore BioVaram’s leadership in biotech innovation, transnational research, and its mission to build a robust, future-ready organization that keeps people at the centre of every breakthrough..

这家公司的开创性工作获得了多项荣誉的认可，包括赢得2025年Maharathi挑战赛、被印度总理选中参观展台，以及在2024年BioAsia被评为前五名初创公司之一。这些成就凸显了BioVaram在生物技术创新、跨国研究方面的领导地位，及其致力于打造一个以人为本、面向未来的强大组织的使命。

Press Contacts

媒体联系人

Akhila Kasireddy

阿希拉·卡西雷迪

Corporate Communication Department, BioVaram

生物维拉姆公司企业传播部

communications＠biovaram.com

communications＠biovaram.com